

At Precipio's clinical lab, our Bloodhound BCR-ABL1 panel goes beyond standard breakpoint testing. It provides **comprehensive diagnostics** in a **simple workflow** with **0.001%** sensitivity for superior **MRD monitoring**. Complementary **ABL1 mutation resistance** and **MPN driver mutation panels** streamline case work-ups while commanding **higher reimbursements**.

Quantitative BCR-ABL1 Panel

Qualitative ABL1 Resistance Panel


Quantitative MPN Panel

Provides Broader Coverage With High Sensitivity




4 Breakpoints for broader coverage and **0.001% sensitivity** for superior detection in initial cases and monitoring expression changes.

Simplifies BCR-ABL1 Testing



Pre-plated reagents allow for fast sample preparation. Automated **analysis software** streamlines interpretation.

Enables Efficient, Comprehensive CML & MPN Workups



Complementary pre-plated molecular assays for **ABL1 Resistance** and **MPN** testing enable efficient, comprehensive reflexive testing for case workup.

Commands Higher Testing Reimbursement



70% higher molecular reimbursement for broader breakpoint testing. Combined with complementary ABL1 resistance mutation and MPN Panel testing increases Precipio lab's overall reimbursement*.

Bloodhound BCR-ABL1, ABL1 Resistance, and MPN tests have been validated as lab developed tests at Precipio. They have not been approved by the FDA.

*Based on Precipio clinical lab's internal data.

For more information please contact:
contact@precipiodx.com | www.precipiodx.com | Tel: +1.203.787.7888